Healthcare Business

Doctor, Health (pulse) copy

Key Movers to Look for Ahead of ASCO

The American Society of Clinical Oncology (ASCO) is in the process of gearing up for its annual meeting. At this meeting, cancer drug developers will share the results from their ...
Read Full Story »
biotech word cloud

8 Speculative Biotech and Biohealth Stocks With Major Analyst Upside Calls

May looked as though it was ignoring the "Sell in May and go away!" mantra. Biotech investors also had to absorb many political jabs over drug pricing, as well as ...
Read Full Story »
FDA_logo

Why Titan Pharmaceuticals Shares Are Rising

Shares of Titan Pharmaceuticals Inc. (NASDAQ: TTNP) saw a handy gain early in Friday’s session following the U.S. Food and Drug Administration (FDA) approval of its partner’s opioid dependence treatment. Specifically, ...
Read Full Story »
Microbe

Thermo Fisher Pays $4.2 Billion for Microscope Maker

Scientific instrument maker and supplier Thermo Fisher Scientific Inc. (NYSE: TMO) said Friday morning that it has agreed to acquire FEI Co. (NASDAQ: FEIC) for $107.50 per share in cash, ...
Read Full Story »
graph

Analyst Has 2 Biotech Stocks to Buy With at Least 100% Upside Potential

Needless to say, the biotech world has had a very difficult year. Even the biggest and the best companies, many of which trade cheaper than big pharmaceutical companies, have suffered ...
Read Full Story »
Female patient on gurney

Why Minerva’s Incredible Move May Be Justified

Minerva Neurosciences Inc. (NASDAQ: NERV) saw its shares make absolutely massive gains on Thursday following the release of positive results from a couple mid-stage clinical trials. Specifically the company announced ...
Read Full Story »
Test tubes

Ionis Pharmaceuticals Drops on Dismissed Study

Ionis Pharmaceuticals Inc. (NASDAQ: IONS) shares dropped severely after a less-than positive update on its IONIS-TTR Rx program. The company is currently evaluating IONIS-TTRRx in an ongoing Phase 3 study, ...
Read Full Story »
bigger fish

How Medivation Shareholders May Lose Big by Poison Pill in Hostile Takeover Fight With Sanofi

Sanofi S.A. (NYSE: SNY) wants Medivation Inc. (NASDAQ: MDVN) and it is going to extreme lengths to get it. Usually the term “hostile takeover” is an exaggeration, but in this case ...
Read Full Story »
Female patient on gurney

OvaScience Prices Secondary Offering

OvaScience Inc. (NASDAQ: OVAS) shares dropped early on Thursday following the pricing of its secondary offering. The company announced that it has priced its secondary offering of 7.15 million shares ...
Read Full Story »
100 dollar bills

Capital Infusions Are More Evidence of a Biotech Turnaround

The collapse of biotech giant Valeant Pharmaceuticals International Inc. (NYSE: VRX) has accelerated and possibly prolonged the biotech decline, infecting the entire sector. While negative news from the company and ...
Read Full Story »
mosquito

7 Companies in the Fight to Defeat the Zika Virus

In 2016, it is the Zika virus that has the public worried about the next pandemic. Past scares have been around Ebola, E. coli, SARS, mad cow, swine flu and ...
Read Full Story »
IPO

Selecta Biosciences Files for IPO

Selecta Biosciences has filed an S-1 form with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO). No pricing details were listed in the filing, but the offering ...
Read Full Story »
clinical trials

Why Sarepta’s PDUFA Delay Is a Good Thing

Sarepta Therapeutics Inc. (NASDAQ: SRPT) shares saw a handy gain on Wednesday following an analyst upgrade. Janney Montgomery Scott has a Neutral rating on Sarepta but increased its fair value estimate to ...
Read Full Story »
child with cancer

Cellectar Wins Big on New Patent

Cellectar Biosciences Inc. (NASDAQ: CLRB) watched its shares skyrocket on Wednesday morning following the announcement of a patent. The company announced that it has obtained a patent that covers CLR 1603, ...
Read Full Story »
Pfizer

4 UBS Most Preferred Pharmaceutical Stocks That Pay Big Dividends

Needless to say, the health care sector, especially pharmaceuticals and biotech, have taken a rhetorical beating from politicians looking to force the blame for high drug prices on some of the ...
Read Full Story »